Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET
2010

Testing New Drug Combinations for Gastrointestinal Tumors

Sample size: 36 publication Evidence: moderate

Author Information

Author(s): Maria Pantaleo, Giordano Nicoletti, Cristina Nanni, Chiara Gnocchi, Lorena Landuzzi, Carmelo Quarta, Stefano Boschi, Margherita Nannini, Monica Di Battista, Paolo Castellucci, Stefano Fanti, Pier Luigi Lollini, Elena Bellan, Mauro Castelli, Domenico Rubello, Guido Biasco

Primary Institution: University of Bologna, Bologna, Italy

Hypothesis

Can combinations of KIT/PDGFRA and mTOR inhibitors improve treatment outcomes in gastrointestinal stromal tumors (GISTs)?

Conclusion

Everolimus was found to be the most effective treatment, especially when combined with imatinib, in controlling tumor growth and metabolism in GISTs.

Supporting Evidence

  • All drugs showed an anti-tumor effect in GIST xenografts.
  • Everolimus alone was superior to nilotinib and imatinib.
  • The combination of everolimus and imatinib was the most effective in reducing tumor growth and metabolism.

Takeaway

Researchers tested different drug combinations to see which worked best against stomach tumors, and found that one combination worked really well.

Methodology

Mice with GIST tumors were treated with various drug combinations, and tumor growth and metabolism were measured using PET imaging.

Limitations

The study was conducted in a small animal model, which may not fully replicate human responses.

Participant Demographics

Rag2-/-; γcommon -/- male mice were used in the study.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1756-9966-29-173

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication